Kolexia
Guillaume Thierry Médecine interne
Guillaume Thierry
Médecine interne
Hôpital Hôtel-Dieu Nantes
Nantes, France
311 Activités
31 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémies Maladie du greffon contre l'hôte Leucémie aigüe myéloïde Leucémie myéloïde Syndromes myélodysplasiques Lymphomes Tumeurs hématologiques Leucémie-lymphome lymphoblastique à précurseurs B et T COVID-19

Collaborateurs

Voir plus
Chevallier Patrice
Chevallier Patrice
Hôpital Hôtel-Dieu Nantes, Nantes, France
Peterlin Pierre
Peterlin Pierre
Hôpital Hôtel-Dieu Nantes, Nantes, France
Moreau Philippe
Moreau Philippe
Hôpital Hôtel-Dieu Nantes, Nantes, France
Garnier Alice
Garnier Alice
Hôpital Hôtel-Dieu Nantes, Nantes, France

Industries

Voir plus
B3TSI
29 collaboration(s)
Dernière en 2023
A+A
26 collaboration(s)
Dernière en 2023
Pfizer
3 collaboration(s)
Dernière en 2021
Zeste Research
2 collaboration(s)
Dernière en 2020

Dernières activités

Voir plus
Post-transplant cyclophosphamide versus anti-thymocyte globulin after reduced intensity peripheral blood allogeneic cell transplantation in recipients of matched sibling or 10/10 HLA matched unrelated donors: final analysis of a randomized, open-label, multicenter, phase 2 trial.
Blood cancer journal   19 février 2024
Phase I study of zoledronic acid combined with escalated doses of interleukine-2 for early in vivo generation of Vγ9Vδ2 T-cells after haploidentical stem cell transplant with posttransplant cyclophosphamide.
American journal of hematology   02 janvier 2024
A Phase 2 Study of Ponatinib for Prevention of Relapse after Allotransplantation in FLT3-ITD + AML Patients : The Ponallo Trial
65th ASH Annual Meeting Abstracts   02 novembre 2023
Sequential Conditioning Regimen with Thiotepa, Clofarabine and Busulfan (TEC/CloB2A2) and Post-Transplant Cyclophosphamide in Adults with Refractory AML: A Retrospective Monocentric Study
65th ASH Annual Meeting Abstracts   02 novembre 2023
Pre-Graft Vaccination or Infection Do Not Provide More Protection Against COVID-19 Infections in Post-Graft Vaccinated Recipients of Allogeneic Stem Cell Transplantation
65th ASH Annual Meeting Abstracts   02 novembre 2023
Comparison of Two Reduced Intensity Conditioning Regimens (Baltimore with Clofarabine vs Thiotepa-Busulfan-Fludarabine) in Adults Receiving Peripheral Blood Stem Cell Haploidentical Transplantation for Myeloid Malignancies: A Retrospective Study of the SFGM-TC
65th ASH Annual Meeting Abstracts   02 novembre 2023
Pre-Graft Immune Status Predicts Survivals and Relapse in Adults Receiving Matched Peripheral Blood Stem Cell Allotransplants for Myeloid Malignancies
65th ASH Annual Meeting Abstracts   02 novembre 2023
HILDEGAZ: Phase 1 Dose Escalation of Early Infusion of Zoledronic Acid in Combination With Increasing Low-dose of Interleukin-2 in Order to Expand Vγ9Vδ2 T Cells After T-replete Haplo-identical Allogeneic Stem Cell Transplantation (SCT)
Essai Clinique (CHU Nantes)   05 octobre 2023
Tocilizumab in combination with a standard induction chemotherapy in acute myeloid leukaemia patients (TOCILAM study): a single-centre, single-arm, phase 1 trial.
EClinicalMedicine   28 septembre 2023
Assessment of monocytic-myeloid-derived suppressive cells (M-MDSC) before and after allogeneic hematopoietic stem cell transplantation in acute leukemia patients.
EJHaem   21 septembre 2023